AEON Biopharma Inc. (AMEX: AEON)’s stock price has dropped by -49.40 in relation to previous closing price of 3.36. Nevertheless, the company has seen a loss of -66.47% in its stock price over the last five trading days. Zacks Investment Research reported 2024-04-19 that After losing some value lately, a hammer chart pattern has been formed for AEON Biopharma, Inc. (AEON), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Is It Worth Investing in AEON Biopharma Inc. (AMEX: AEON) Right Now?
The stock has a 36-month beta value of 0.76. Opinions on the stock are mixed, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for AEON is 11.45M, and at present, short sellers hold a 3.78% of that float. On May 06, 2024, the average trading volume of AEON was 70.02K shares.
AEON’s Market Performance
AEON stock saw a decrease of -66.47% in the past week, with a monthly decline of -79.37% and a quarterly a decrease of -76.39%. The volatility ratio for the week is 23.29%, and the volatility levels for the last 30 days are 15.56% for AEON Biopharma Inc. (AEON). The simple moving average for the past 20 days is -71.32% for AEON’s stock, with a -76.28% simple moving average for the past 200 days.
Analysts’ Opinion of AEON
Many brokerage firms have already submitted their reports for AEON stocks, with H.C. Wainwright repeating the rating for AEON by listing it as a “Buy.” The predicted price for AEON in the upcoming period, according to H.C. Wainwright is $18 based on the research report published on August 18, 2023 of the previous year 2023.
AEON Trading at -82.09% from the 50-Day Moving Average
After a stumble in the market that brought AEON to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -90.10% of loss for the given period.
Volatility was left at 15.56%, however, over the last 30 days, the volatility rate increased by 23.29%, as shares sank -79.76% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -83.73% lower at present.
During the last 5 trading sessions, AEON fell by -66.47%, which changed the moving average for the period of 200-days by -79.91% in comparison to the 20-day moving average, which settled at $5.5935. In addition, AEON Biopharma Inc. saw -76.39% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at AEON starting from Strathspey Crown Holdings Grou, who sale 7,380,394 shares at the price of $10.00 back on Aug 11 ’23. After this action, Strathspey Crown Holdings Grou now owns 2,031,773 shares of AEON Biopharma Inc., valued at $73,803,940 using the latest closing price.
Stock Fundamentals for AEON
The total capital return value is set at 7.81. Equity return is now at value -27.38, with -13.94 for asset returns.
Based on AEON Biopharma Inc. (AEON), the company’s capital structure generated -0.0 points at debt to capital in total, while cash flow to debt ratio is standing at -128.0.
Currently, EBITDA for the company is -48.36 million with net debt to EBITDA at 0.1. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.48.
Conclusion
To sum up, AEON Biopharma Inc. (AEON) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
